Diabetes drug 'may aid weight loss' Share: Save: Subscribe. Patients with diabetes lost on average 2.8kg more than diabetic patients in control groups. Diabulimia: Diabetics skipping insulin injections to. The diabetes drug liraglutide. Although this study didn't compare Victoza with other weight loss. 3,731 obese and overweight adults to take daily injections of. Victoza Approved For Weight LossLiraglutide injections could help to treat. The researchers stress the importance of weight loss research by highlighting the fact that obesity has risen. Saxenda is the fourth drug for weight loss OK'd by the agency since 2012. It's already available in a lower dose as Victoza for type 2. Diabetes Drug Victoza Spurs Weight Loss. The diabetes drug liraglutide (Victoza) may help obese people without the disease lose weight, a new study suggests. John Wilding, head of the department of obesity and endocrinology at the University of Liverpool in England. People taking Xenical lose an average of five to seven pounds, studies have shown. Victoza works by lowering blood sugar. The results of the study were scheduled for presentation Thursday at the European Congress on Obesity in Sofia, Bulgaria. Data and conclusions presented at meetings are usually considered preliminary until published in a peer- reviewed medical journal. Dr. David Katz, director of the Yale University Prevention Research Center in New Haven, Conn., wasn't surprised by the findings. Lowering blood sugar results in weight loss, he said. Whether Victoza improves long- term weight management or leads to better health outcomes over years when used for weight loss is unknown, he said. And they had to increase physical activity by walking briskly for 3. Many participants (6. The researchers found that almost two- thirds of those taking Victoza lost 5 percent or more of their body weight, and one- third lost 1. Among those taking the placebo, 2. People taking Victoza also saw a drop in their blood sugar, blood pressure and cholesterol, the study found. Based on these phase 3 trial findings, drug maker Novo Nordisk is asking the U. S. Food and Drug Administration to approve Victoza for weight loss. Phase 3 is the final step in the drug- approval process. The most common side effects were nausea and diarrhea. Most of these were mild and short- lived, the researchers said. Gallbladder and pancreas problems (pancreatitis) were more common among those taking Victoza, but the numbers were small. About 1. 0 percent of the participants in both groups left the study because of side effects. Wilding has served as a consultant to Novo Nordisk, which funded the study. Special: These Are the Deadliest Foods in America.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |